Advert Janssen

Pre-licence promotion and breach of undertaking

For promoting Tremfya (guselkumab) for an unlicensed indication and failing to comply with its previous undertaking, Janssen was ruled in breach of the following clauses of the Code.

Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry

Clause 3.2 - Promoting a medicine for an unlicensed indication

Clause 9.1 - Failing to maintain high standards

Clause 29 - Failing to comply with an undertaking